
ALZHEIMER’S DISEASE (AD) CAN BE DIFFICULT TO DIAGNOSE1-3
An AD diagnosis can be challenging due to overlapping symptoms with other causes of cognitive impairment, particularly in early stages when symptoms may mimic the natural aging process.
Objective evidence can help increase confidence in AD diagnosis3-5
With the approval of amyloid-targeting therapies, confirming amyloid pathology as early as possible is more important than ever for patients being assessed for AD.2,6,7
- Nearly 1 in 3 people clinically diagnosed with AD based on symptoms did not test positive for amyloid plaques8-10
- Knowing that β-amyloid plaques are not present may support the choice to assess for other causes of cognitive impairment and help avoid unnecessary treatment11-14
Based on a comparison of diagnostic confidence pre- and post-amyloid PET scans in a study of patients with cognitive impairment of unknown etiology or suspected AD, diagnostic uncertainty was reduced from 72% before amyloid PET to 16% after amyloid PET scan.8
Learn more about the efficacy of Amyvid
CHOOSE AMYVIDPET=positron emission tomography.
References:
- Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022;18(4):700-789.
- Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
- Amyvid (florbetapir F 18 injection) Prescribing Information. Lilly USA, LLC.
- Clark CM, Schneider JA, Bedell BJ, et al; for the AV45-A07 Study Group. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305(3):275-283.
- Pemberton HG, Collij LE, Heeman F, et al; on behalf of AMYPAD consortium. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508-3528.
- Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. doi:10.1186/s13195-017-0283-5
- Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286-1294.
- Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4-15.
- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition in Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562.
- Ty D, McDermott M. Building workforce capacity to improve detection and diagnosis of dementia. Milken Institute; 2021. Accessed August 12, 2021. https://milkeninstitute.org/sites/default/files/2021-05/Building%20Dementia%20Workforce.pdf
- Prince M, Bryce R, Ferri C. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. Alzheimer’s Disease International; September 2011. Accessed October 19, 2016. https://www.alz.co.uk/research/WorldAlzheimerReport2011.pdf
- Weidman DA, Zamrini E, Sabbagh MN, et al. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. Neurocase. 2017;23(1):41-51.
- Shea YF, Barker W, Greig-Gusto MT, et al. Utility of amyloid PET scans in the evaluation of patients presenting with diverse cognitive complaints. J Alzheimers Dis. 2018;66(4):1599-1608.
- Balasa M, Gelpi E, Antonell A, et al; for Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology. 2011;76(20):1720-1725.
- Boccardi M, Altomare D, Ferrari C, et al. et al; Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol. 2016;73(12):1417-1424.
- Dubois B, Padovani A, Scheltens P, et al. Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alzheimers Dis. 2016;49(3):617-631.
- Porteri C, Albanese E, Scerri C, et al; Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers. The biomarker-based diagnosis of Alzheimer’s disease. 1—ethical and societal issues. Neurobiology Aging. 2017;52:132-140.
- Liss JL, Seleri Assunção S, Cummings J, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021;290(2):310-334.